ArticleBMJ open2025

Design and methods of the Ixekizumab Diabetes Intervention Trial (I-DIT): protocol for a phase 2, randomised, multicentre, placebo-controlled, double-blind trial of anti-interleukin 17 as a treatment option for adults with new-onset type 1 diabetes.

Shilan Seyed Ahmadi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.